Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 6% – Still a Buy?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) shares shot up 6% on Thursday . The stock traded as high as $1.25 and last traded at $1.24. 94,208 shares changed hands during mid-day trading, a decline of 35% from the average session volume of 145,177 shares. The stock had previously closed at $1.17.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ENLV shares. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Enlivex Therapeutics in a report on Friday, September 27th. D. Boral Capital reiterated a “buy” rating and set a $13.00 target price on shares of Enlivex Therapeutics in a report on Wednesday, December 11th.

Enlivex Therapeutics Price Performance

The stock has a market cap of $26.76 million, a P/E ratio of -1.28 and a beta of 1.01. The stock’s 50 day simple moving average is $1.20 and its two-hundred day simple moving average is $1.33.

Institutional Investors Weigh In On Enlivex Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in shares of Enlivex Therapeutics in the 2nd quarter valued at about $35,000. Sigma Investment Counselors Inc. acquired a new position in shares of Enlivex Therapeutics during the third quarter worth about $50,000. Finally, Armistice Capital LLC bought a new position in shares of Enlivex Therapeutics during the second quarter worth about $2,415,000. 1.02% of the stock is owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.